Supradamal
Supradamal is a peptidyl-prolyl cis-trans isomerase (PPIase) inhibitor with an IC50 of 83 nM against *Plasmodium falciparum* and an IC50 of 75 nM against *Plasmodium vivax*. Supradamal inhibits the development, maturation and in vitro growth of *Plasmodium falciparum* trophozoites. Supradamal is applicable to malaria-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 71458-51-0
- Formule: C17H21N3O2
- Masse moléculaire:299.37
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
Supradamal inhibits the growth of Plasmodium falciparum in human red blood cells, including the development of trophozoites[1].
Supradamal (Compound 4a) inhibits the peptidyl-prolyl isomerase activity of purified Plasmodium falciparum FKBD35, with an IC50 of 83 nM[3].
Supradamal inhibits the peptidyl-prolyl isomerase activity of purified Plasmodium vivax FKBD35 with an IC50 of 75 nM[3].
Supradamal (48 h) inhibits the growth of *Plasmodium falciparum* strain 3D7 in vitro by specifically interfering with the development of the trophozoite stage, while exerting no effect on ring-stage parasites[3].
Supradamal (500 nM; 4-16 h) specifically inhibits the development of trophozoite-stage parasites of the Plasmodium falciparum 3D7 strain, with no effect on ring-stage or schizont-stage parasites[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 71458-51-0
-
Masse moléculaire 299.37
-
Formule C17H21N3O2
-
SMILES
O=C(C1=CC=NC=C1)NNC(C23CC4CC(C3)CC(C2)C4)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[2]. Rasch J, et al. Novel Cycloheximide Derivatives Targeting the Moonlighting Protein Mip Exhibit Specific Antimicrobial Activity Against Legionella pneumophila. Frontiers in bioengineering and biotechnology. 2015;3:41. [Content Brief]
[3]. Harikishore A, et al. Adamantyl derivative as a potent inhibitor of Plasmodium FK506 binding protein 35. ACS medicinal chemistry letters. 2013 Nov 14;4(11):1097-101. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz